Inactive Instrument

Actelion Ltd Share Price Swiss Exchange

Stocks

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/05/17	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/05/17	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/04/17	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/04/17	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/04/17	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/03/17	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
22/02/17	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/04/20	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/06/17	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/06/17	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
15/06/17	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/01/18	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/01/18	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/01/18	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/10/17	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+1.80%	-0.83%	+52.79%	+86.50%	54.69B
ARGENX SE	+0.88%	-0.13%	+57.39%	+54.58%	53.79B
BIONTECH SE	+0.18%	+2.13%	-15.22%	-14.97%	23.31B
INSMED INCORPORATED	+1.50%	-1.35%	+5.68%	+415.28%	23.2B
WUXI BIOLOGICS (CAYMAN) INC.	+0.41%	-1.32%	+39.36%	-3.77%	20.03B
GENMAB A/S	+0.30%	-0.40%	+33.13%	-33.46%	17.31B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.98%	-3.91%	+36.38%	+545.99%	15.36B
PHARMAESSENTIA CORPORATION	0.00%	-2.08%	+165.40%	+297.92%	14.99B
EXELIXIS, INC.	+1.06%	+0.63%	+26.80%	+185.02%	13.96B
Average	+0.78%	-1.55%	+44.63%	+170.34%	26.29B
Weighted average by Cap.	+0.96%	-1.50%	+44.48%	+134.11%

Employees

Sector